Date: 2015-07-07
Type of information: Nomination
Compound: head of manufacturing, head of intellectual property
Company: Autolus (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 7th, 2015, Autolus announced that it has recruited Jim Faulkner as head of manufacturing and Louise Holliday as head of intellectual property. Dr Jim Faulkner joins from GSK where he spent 15 years in a series of progressively senior roles within the biopharmaceutical R&D unit, latterly serving as vice president, manufacturing and supply within the GSK Rare Diseases unit. Jim’s role spanned all the unit’s projects and products including their ex vivo autologous gene therapy portfolio, therapeutic oligonucleotides and monoclonal antibodies. Previously Jim worked within small biotech and has also held academic posts. He received a BSc in Biotechnology from Leeds University and a PhD in Molecular Biology in association with the University of Kent and has authored a number of publications and patents in the field of biopharmaceutical development.
- Louise Holliday joins from leading IP firm, D Young and Co LLP, where she was a partner for over 10 years. While at D Young & Co her clients included academic departments, research institutes, start-ups, SMEs and larger biotech companies. She specialised in all types of biotech patent work, in particular molecular immunology, antibodies, vaccines and stem cells. Her caseload involved a significant amount of opinion work, including freedom to operate analysis, due diligence, patentability analysis and advising clients on infringement and validity matters. Prior to joining D Young & Co, Louise worked in private practice in Bristol. She is a Chartered Patent Attorney and a European Patent Attorney. She also holds an MA in Biochemistry from New College, Oxford and a PhD in Molecular Immunology from University College London.
Financial terms:
Latest news:
Is general: Yes
